Compare Enveric Biosciences Inc (ENVB) vs T-Mobile Us Inc (TMUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs T-Mobile Us Inc — how do they compare? Enveric Biosciences Inc trades at $1.56 (market cap $6.20M), while T-Mobile Us Inc trades at $177.18 (market cap $191.56B). The key difference: T-Mobile Us Inc is far larger — about 30896.8× Enveric Biosciences Inc's market cap, and T-Mobile Us Inc pays a 2.28% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | TMUS | |
|---|---|---|
Market Cap | $6.20M | $191.56B |
Sector | Health | Media |
52-Week High | $17.40 | $259.01 |
52-Week Low | $1.27 | $167.65 |
Enterprise Value | $1.30M | $308.17B |
Dividend Yield | — | 2.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.55, up 0.65% with a bullish technical signal. The company shows negative profitability metrics with ROE at -257.95% and ROA at -218.01% for 2025, but has consistently beaten earnings expectations. Recent news highlights positive preclinical data for EB-003 and FDA guidance support for psychedelic drug development. Cash flow remains challenging with negative operational cash flow offset by financing activities.
Despite negative profitability, ENVB's consistent earnings beats and strong analyst support (75% buy rating) suggest potential upside. Key risks include ongoing cash burn and regulatory hurdles in drug development. The stock's technical strength and positive clinical developments provide catalysts, but investors should monitor cash position and regulatory progress closely.
TMUS trades at $177.02, down 0.64% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings, beating EPS estimates with $2.99 actual vs. $2.59 expected, and raised its free cash flow outlook. Revenue growth remains robust, reaching $88.31 billion in 2025, though net income dipped slightly to $10.99 billion. Recent news includes the completion of an $2.9 billion spectrum sale to Grain Management and competitive concerns from SpaceX's Starlink Mobile expansion.
The outlook for TMUS is mixed; strong fundamentals and analyst bullishness with an $233.20 price target suggest upside, but technical bearishness and competitive threats from new entrants like SpaceX pose risks. Earnings momentum and dividend growth support long-term value, yet near-term volatility may persist due to market sentiment and industry disruption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About T-Mobile Us Inc
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →
